Diagnosis of diseases" is in full investment mode

10/04/2013
Diego Gutiérrez
Diagnosis of diseases" is in full investment mode

This sector of activity is immersed in an active movement of both corporate consolidation operations such as the one carried out by Progenika and Griffols as well as by several start-ups that are trying to carve out a niche for themselves in the complicated world of healthcare.

Corporate operations: Grifols acquires Progenika

The Catalan plasma derivatives multinational Grifols has bought 60% of the capital of the Basque biotech firm Progenika Biopharma 37 million in March 2013.
Grifols is the world's third largest producer of plasma-derived biological drugs, and is a pioneering group in the research and development of therapeutic alternatives.
Progenika specialises in the development of technology for personalised medicine, and focuses its activity on the design and production of genomic and proteomic tests for in vitro diagnosis, disease prognosis, response prediction and drug therapy monitoring.
In 2012, Grifols increased its profit fivefold, from 50.3 million euros in 2011 to 256.7 million euros at the end of last year.
The year-on-year profit growth of 410.2 % is explained by the acquisition of its US competitor Talecris, which it closed in June 2011, and the company's strong performance abroad, especially in the US and Canada.

Startups in action: Sword Diagnostic and Chronix

On the other hand, new initiatives are emerging, seeking new rounds of funding, which foresee the further development of new diagnostic systems. Some of these cases are:
 Sword Diagnostics

Espada Diagnostics high-throughput screening technology significantly improves the overall performance of biomedical assays and tests.

– Chronix 

Chronix Biomedical, Inc. is a molecular diagnostics company, developing primarily blood tests for cancer, including companion diagnostics and tests for the detection of minimal residual disease.

More active funds: significant presence of VCs linked to pharmaceutical companies
In the first few months of 2013 we have seen VC funds related to multinational pharmaceutical companies enter the diagnostics sector. An example of this has been the Roche Fund's entry in March in Maculogix.

Diego Gutiérrez Zarza
ABRA INVEST
Web: www.abra-invest.com
Blog: http://abrainvest.wordpress.com/ 

Lastest news

State of technology M&A in Spain | Analysis August 2025

El mes de agosto, tradicionalmente más pausado en cuanto a transacciones corporativas, ha sorprendido en 2025 con una intensa actividad en el ámbito tecnológico en España. Se registraron operaciones de gran calado en segmentos como marketplaces digitales,...

Baker Tilly advises BSG on its acquisition of Copermática

The advisors for the sale and purchase of technology companies at Baker Tilly Tech M&A have advised Business Software Group (BSG) on its recent acquisition of Copermática, a company specialising in management software for professional firms and consultancies. With...

Do you want to sell or buy a company?

We are experts in M&A transactions in the technology sector.

Subscribe to our newsletter

    On which topic would you like to receive information?

    Request for information

    If you want to buy or sell a company, or need more information about our services, do not hesitate to contact us through the form.

    Or if you prefer, call us at:

    +34 946 42 41 42